Cipla Ltd

Cipla Ltd is up for a third straight session in a row. The stock is quoting at Rs 1566.2, up 2.93% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.56% on the day, quoting at 24624.55. The Sensex is at 80559.71, up 0.4%. Cipla Ltd has risen around 5.54% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has risen around 1.12% in last one month and is currently quoting at 21753.5, up 1.87% on the day. The volume in the stock stood at 11.55 lakh shares today, compared to the daily average of 16.48 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1565.2, up 2.54% on the day. Cipla Ltd is up 0.15% in last one year as compared to a 1.99% spurt in NIFTY and a 0.67% spurt in the Nifty Pharma index.The PE of the stock is 23.78 based on TTM earnings ending June 25.Powered by Capital Market - Live

Cipla announced that SES ESG Research, a SEBI registered ESG Rating Provider (SES), has independently assigned the Environmental, Social, and Governance (ESG) Rating of 69.3 (Grade B) (Adjusted) from 70.2 (Grade B+) (Adjusted) to the Company.Powered by Capital Market - Live

The classification was communicated to the company via email on 4 August 2025. The inspection was conducted under the USFDA's current Good Manufacturing Practices (cGMP) framework from 26 May to 30 May 2025. In an earlier exchange filing dated May 30, Cipla had disclosed that the inspection concluded with one observation issued in Form 483. The company reiterated its commitment to compliance and stated that it will work closely with the USFDA to address the observation comprehensively within the stipulated timeframe. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. Cipla reported 10.18% increase in consolidated net profit to Rs 1,297.62 crore on a 3.93% rise in total revenue from operations to Rs 6,957.47 crore in Q1 FY26 over Q1 FY25. The counter shed 1.42% to Rs 1,494 on the BSE Powered by Capital Market - Live

Cipla announced that the United States Food and Drug Administration has classified the current Good Manufacturing Practices inspection of the company's manufacturing facility in Bommasandra, Bengaluru as Voluntary Action Indicated (VAI).Powered by Capital Market - Live

Profit before tax (PBT) stood at Rs 1,769.93 crore in Q1 FY26, marking an 9.84% increase from Rs 1,611.36 crore reported in the same quarter last year. EBITDA rose 3.6% to Rs 1,778 crore in Q1 FY26, as against Rs 1,716 crore reported in Q1 FY25. The EBITDA margin remained stable at 25.6%. The company's One India Business delivered a growth of 6% YoY for the quarter, breaching the threshold of Rs 3,000 crore for the first time ever in the opening quarter of any financial year. In North America, Cipla reported quarterly revenue of $226 million, driven by strong traction in differentiated assets. Key launches during the quarter included Nano Paclitaxel vials (ANDA) and Nilotinib Capsules (NDA). The One Africa region continued its growth momentum, recording an 11% YoY increase in revenue (USD terms). Cipla's prescription business ranked No. 2 in the market. Emerging Markets and Europe also performed well, registering a healthy 8% YoY revenue growth in USD terms. The company's R&D investments stood at Rs 432 crore, accounting for 6.2% of sales. The expenditure was primarily directed toward product filings and development initiatives. The company reported a strong net cash position of Rs 10,379 crore. The company's debt primarily comprises lease liabilities and working capital requirements. Umang Vohra, MD and Global CEO, Cipla, said, 'I am pleased to share that we continue to make considerable progress across our focused markets. In Q1FY26, we delivered steady revenue of Rs 6,957 crore, with a healthy EBITDA margin of 25.6%. What makes this performance commendable is that it builds on a strong prior-year quarter, where we achieved our highest-ever US Generics revenue. Our One-India business grew at 6% YoY. Key therapies in the branded prescription business continued to outpace the market growth, trade generics recorded strong growth, and anchor brands of the consumer health business maintained their leadership position. With positive traction in our differentiated assets, the US business posted a revenue of $226 Mn. In One Africa, we achieved a solid growth of 11% YoY in USD terms. Emerging Markets and Europe delivered a healthy revenue growth of 8% YoY in USD terms on the back of a deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in the future pipeline, as well as focusing on resolutions on the regulatory front. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. Powered by Capital Market - Live

Net profit of Cipla rose 10.19% to Rs 1297.62 crore in the quarter ended June 2025 as against Rs 1177.64 crore during the previous quarter ended June 2024. Sales rose 3.20% to Rs 6837.04 crore in the quarter ended June 2025 as against Rs 6624.86 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales6837.046624.86 3 OPM %26.0125.90 - PBDT2022.651858.04 9 PBT1769.931611.36 10 NP1297.621177.64 10 Powered by Capital Market - Live

Cipla will hold a meeting of the Board of Directors of the Company on 25 July 2025.Powered by Capital Market - Live

Cipla has allotted 43,396 fully paid-up equity shares of Rs 2 each, pursuant to exercise of employee stock options / stock appreciation rights under the Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company. Powered by Capital Market - Live

Cipla Ltd is up for a fifth straight session today. The stock is quoting at Rs 1517.2, up 0.42% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.38% on the day, quoting at 25199.55. The Sensex is at 82711.36, up 0.39%. Cipla Ltd has gained around 0.37% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has gained around 4.47% in last one month and is currently quoting at 21948, up 0.45% on the day. The volume in the stock stood at 6.69 lakh shares today, compared to the daily average of 19.71 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1524.2, up 0.71% on the day. Cipla Ltd is down 1.54% in last one year as compared to a 8.05% jump in NIFTY and a 11.69% jump in the Nifty Pharma index.The PE of the stock is 24.77 based on TTM earnings ending March 25.Powered by Capital Market - Live

Cipla announced that Cipla (EU), UK, a wholly owned subsidiary of the Company, has incorporated a new wholly owned subsidiary named 'CiplaRna GmbH' in Germany, effective 28 May 2025. CiplaRna has been incorporated with the objective of establishing a laboratory for mRNA-based formulation and drug development support.Powered by Capital Market - Live